OrbiMed Advisors
http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.
View Older Stories View More Recent Stories
-
Form SC 13D Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 4 Inspire Medical Systems, For: Mar 03 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Alector, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 3 Passage BIO, Inc. For: Feb 27 Filed by: ORBIMED ADVISORS LLC
-
Natera (NTRA) Tops Q4 EPS by 9c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus
-
Natera Reports Fourth Quarter and Year 2019 Financial Results
-
Innovate Biopharmaceuticals Announces Acceptance of Three Abstracts for the 2020 Digestive Disease Week (DDW) Conference
-
Form SC 13G Krystal Biotech, Inc. Filed by: ORBIMED ADVISORS LLC
-
Innovate Biopharmaceuticals Announces Shareholder Approval of All Proposals in Connection with the Pending Merger with RDD Pharma Ltd. to Create 9 Meters Biopharma, a GI-focused Platform Company
-
Form SC 13G/A Deciphera Pharmaceutical Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A eHealth, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G MeiraGTx Holdings plc Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G Applied Therapeutics Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G Krystal Biotech, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A ARVINAS, INC. Filed by: ORBIMED ADVISORS LLC
-
Form 13F-HR ORBIMED ADVISORS LLC For: Dec 31
-
Form SC 13G/A Inspire Medical Systems, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Clovis Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Aeglea BioTherapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G Prothena Corp plc Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A PUMA BIOTECHNOLOGY, INC. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G Adverum Biotechnologies, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G Crinetics Pharmaceutical Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D Arcutis Biotherapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form 4 Xtant Medical Holdings, For: Feb 05 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Alector, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A SELECTA BIOSCIENCES INC Filed by: ORBIMED ADVISORS LLC
-
MRI Interventions, Inc. Closes $17.5 Million Strategic Investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital Management
-
Bloom Burton & Co. Announces the 2020 Bloom Burton Award Gala
-
Ikena Oncology Announces Dosing of First Patient in Phase 1 Study Evaluating IK-175 in Patients with Advanced Solid Tumors
-
Harmony Biosciences Secures $200 Million Debt Facility
-
PlacementTracker Publishes 2019 PIPE and Private Placement Markets League Tables
-
Foamix Announces OrbiMed’s Support of Merger with Menlo Therapeutics
-
OrbiMed Supports the Proposed Foamix Pharmaceuticals Ltd. And Menlo Therapeutics Inc. Merger
-
Emendo Biotherapeutics Raises $61 Million to Advance Next Generation Genome Editing Therapeutics
-
Form SC 13D/A Alector, Inc. Filed by: ORBIMED ADVISORS LLC
-
Mri Interventions, Inc. (MRIC) Obtains $17.5 Million Strategic Investment from PTC Therapeutics (PTCT) and Petrichor Healthcare Capital Management
-
MRI Interventions, Inc. Obtains a $17.5 Million Strategic Investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital Management
-
Allergan and Avitide Expand Partnership to Develop Custom Affinity Chromatography Technologies
-
Sonendo® Announces Growth Investment from EW Healthcare Partners
-
Form SC 13D/A Nabriva Therapeutics Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Alector, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Principia Biopharma Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Tricida, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 4 Tricida, Inc. For: Dec 11 Filed by: ORBIMED ADVISORS LLC
-
PMV Pharma Appoints Leila Alland, M.D., as Chief Medical Officer
-
Gemini Therapeutics and Avitide Enter Into Exclusive License Agreement
-
Form SC 13D/A Nabriva Therapeutics Filed by: ORBIMED ADVISORS LLC
-
Kyn Therapeutics Rebrands as Ikena Oncology, Reflecting Next Phase of Growth

